media – Page 113 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Novel AI-Based Analysis Method Uncovers New Insight into ALS Progression

Amyotrophic Lateral Sclerosis (ALS) is a fatal condition where motor neurons, which are crucial for controlling movement, progressively die. Currently, there is no cure for ALS, and patients typically live between 2 and 5 years after diagnosis. Now, in a new study published in Science Advances, researchers have shown how to leverage artificial intelligence (AI) to gain deeper insights into ALS progression. The study, led by researchers from the School of Psychology and Neuroscience at the University of St Andrews (Scotland, UK), in collaboration with the Department of Neuroscience, University of Copenhagen (Copenhagen, Denmark), found that certain neural circuits that control movement are compromised early in the disease, while others deteriorate later as the disease progresses. The techniques used in the study allow for the simultaneous analysis of multiple cell types within the spinal cord, enhanced by an innovative AI-driven analytical method. This enabled the identification of specific networks of ...
- Source: drugdu
- 77
- July 4, 2024
FDA Approves Lilly’s Kisunla for the Treatment of Early Symptomatic Alzheimer’s Disease

By Don Tracy, Associate Editor Kisnula is the first amyloid plaque-targeting therapy that allows for stopping treatment upon plaque removal, company says. The FDA has approved Eli Lilly’s Kisunla (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion) to treat adults with early symptomatic Alzheimer’s disease, including mild cognitive impairment and mild dementia with confirmed amyloid pathology. According to the company, Kisunla the first amyloid plaque-targeting therapy that allows for stopping treatment upon plaque removal, potentially reducing costs and infusion frequency. Approval was based on results from the Phase III TRAILBLAZER-ALZ 2 study.1 “Kisunla demonstrated very meaningful results for people with early symptomatic Alzheimer’s disease, who urgently need effective treatment options. We know these medicines have the greatest potential benefit when people are treated earlier in their disease, and we are working hard in partnership with others to improve detection and diagnosis,” said Anne White, EVP, president, Lilly Neuroscience, Eli ...
- Source: drugdu
- 107
- July 4, 2024
Eli Lilly Alzheimer’s Drug Lands FDA Approval, Introducing Competition to Eisai’s Leqembi

Eli Lilly’s Kisunla is now FDA approved for treating patients in the early stages of Alzheimer’s disease. In addition to slowing cognitive decline and disease progression, clinical trial results showed that amyloid beta plaques were reduced to the point where some patients could stop taking the infused therapy. By Frank VinluanEli Lilly Alzheimer’s disease drug has received its long-awaited FDA approval, bringing patients a treatment that works similarly to an Eisai medication for the neurodegenerative disorder but with dosing advantages that patients might prefer. The Tuesday regulatory decision comes less than a month after an FDA advisory committee voted unanimously that the benefits of the Lilly drug in slowing cognitive decline outweigh its safety risks. The approval covers the treatment of Alzheimer’s patients with mild cognitive impairment or mild dementia, the same population that was evaluated in clinical trials. Known in development as donanemab, Lilly will market its new Alzheimer’s ...
- Source: drugdu
- 134
- July 4, 2024
Female cancer survivors at low risk of developing obstetric complications

According to WHO, around 15% of pregnant women will develop an obstetric complication Researchers from the Universities of Birmingham, Bristol and Edinburgh have revealed that the majority of women who have survived cancer are at low risk of developing obstetric complications. The study published in the Lancet Oncology was funded by Children with Cancer UK, the Brain Tumour Charity and the Academy of Medical Sciences. Currently the most prevalent cancer in the UK, breast cancer affects around 55,000 women every year. According to the World Health Organization, around 15% of all pregnant women will develop a potentially life-threatening obstetric complication, including pyrexia and sepsis intrapartum haemorrhage, in pregnancy and childbirth and some will require a major obstetrical intervention to survive. After analysing data from almost 100,000 female survivors of cancer who had been diagnosed between the ages of 15 and 39 years between 1971 and 2006, approximately 21,437 births had ...
- Source: drugdu
- 113
- July 4, 2024
Researchers find whole genome sequencing improves care for paediatric cancer

Affecting around 3,755 young people in the UK every year, leukaemia is the most commonly diagnosed cancer in children Researchers from the Wellcome Sanger Institute, Cambridge University Hospitals NHS Trust, Great Ormond Street Hospital and the University of Cambridge have revealed that whole genome sequencing (WGS) can improve the clinical care of children with cancer. Published in Nature Medicine, the study showed that cutting-edge genomic testing could improve the management of care in real-time while providing more benefits compared to all other current tests combined. Every year, around 3,755 young people are diagnosed with cancer in the UK, with some of the most prevalent childhood cancers including lymphoma, muscle or bone cancers, neuroblastoma and leukaemia, which is the most commonly diagnosed cancer in children. WGS is a single test that provides a complete readout of the tumour’s entire genetic code while identifying every single cancer-causing mutation. Researchers, for the first ...
- Source: drugdu
- 102
- July 4, 2024
Henlius Receives Approval in Japan for Phase 3 MRCT of Anti-PD-1 mAb Serplulimab Combo on First-Line mCRC

Shanghai, China, July 2, 2024 – Shanghai Henlius Biotech, Inc. (2696.HK) announced that the clinical trial notification (CTN) for phase 3 international multicenter clinical study (ASTRUM-015) of Henlius’ self-developed anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG (serplulimab) in combination with bevacizumab and chemotherapy in patients with metastatic colorectal cancer (mCRC) has been permitted by Japan’s Pharmaceuticals and Medical Devices Agency. The study has previously completed dosing of the first subject in China, and the regulatory registration and clinical development is advancing efficiently in more countries and regions around the world. Colorectal cancer (CRC) is one of the most common malignant cancers globally. Over 1.9 million newly diagnosed cases and more than 900,000 deaths were estimated in 2022, and the incidence rates were highest in Europe and Oceania [1]. It is estimated that, by 2040, the burden of CRC will increase to 3.2 million new cases per year (an increase of 63%) and ...
- Source: drugdu
- 106
- July 4, 2024
Hengrui Pharmaceuticals Bupivacaine Liposome Injection Approved for Marketing in the United States

Today, Hengrui Pharmaceuticals Bupivacaine Liposome Injection was successfully approved for listing in the United States. This product is the first generic drug of this species approved for marketing in the world, and its listing in the U.S. is an important milestone in the international development of the company’s high-end preparations. Bupivacaine liposome injection was first approved in the United States in 2011, and the original product is currently sold only in the United States and Europe, and has not been imported domestically. Because of its high technical barriers, no generic product has been successfully listed for more than 10 years. Hengrui Pharmaceuticals Bupivacaine Liposome Injection has been approved to be listed in China at the end of 2022, which is the exclusive global first generic of Hengrui Pharmaceuticals’ Class 3 new drug, deemed to have passed the consistency evaluation, and is also the first ultra-long-acting local anesthesia drug in China, ...
- Source: drugdu
- 164
- July 4, 2024
First-Of-Its-Kind Integrated Heart Mapping to Prevent Damage Caused By Heart Attack

During and after a heart attack, the heart’s muscles suffer damage leading to the formation of scar tissue known as cardiac fibrosis. This scar tissue lacks the flexibility and contractility of healthy heart muscle, and its permanent presence can impair the heart’s pumping ability, potentially resulting in heart failure. Cardiac fibrosis is associated with all forms of heart disease, including those resulting from the overloading of the heart due to high blood pressure. Despite substantial investment in research seeking treatments to manage cardiac fibrosis, these efforts have largely been unsuccessful. There is a pressing need for innovative treatments that could halt or even reverse cardiac fibrosis, offering hope to millions affected. Scientists have now developed a first-of-its-kind integrated map of heart cells that sheds light on the process of cardiac fibrosis and could aid in preventing damage following a heart attack. This breakthrough achieved by researchers at the Victor Chang ...
- Source: drugdu
- 120
- July 3, 2024
Nanotech to Further Enhance Sensitivity and Accuracy of ELISA Testing for Cancer Screening

The early detection of serious diseases such as cancer or dementia is crucial for effective treatment and improving survival rates. One of the leading methods used for this purpose is the enzyme-linked immunosorbent assay (ELISA), a popular technology in disease screenings. Building upon previous advancements in nanoparticle research, scientists are now working on further enhancing the sensitivity and accuracy of ELISA tests for detecting cancers and other diseases. The promising nanoparticle research being conducted by Associate Professor Xiaohu Xia at the University of Central Florida’s (UCF, Orlando, FL, USA) Department of Chemistry has the potential to increase the accuracy of disease detection by over 300 times compared to current market standards. Supported by a USD 1.3 million grant from the National Institutes of Health, Xia’s four-year project aims to boost the diagnostic performance of ELISA tests by utilizing custom-designed nickel-platinum nanoparticles that attach to specific disease markers like proteins and ...
- Source: drugdu
- 111
- July 3, 2024
ICL granted £150,000 to explore link between breast cancer and breastfeeding

Breast cancer is the most common cancer in the UK, accounting for 15% of all cancersImperial College London (ICL) researchers have been awarded £150,715 by Breast Cancer Now to investigate the links between breast cancer and breastfeeding in women.Currently the most common cancer in the UK, breast cancer affects around 55,000 women every year and accounts for 15% of all cancer cases in the UK. The disease occurs when abnormal breast cells grow out of control and form tumours. Previous research has already shown that breastfeeding is linked to a lower risk of developing breast cancer. Data analysis has shown that the risk of developing the disease decreases by 4% for every 12 months of breastfeeding. Researchers have estimated that this is due to breastfeeding altering the balance of hormones in the body, protecting breast cells and making them less vulnerable to changes that cause cancer. In addition, ICL researchers ...
- Source: drugdu
- 79
- July 3, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.